Health
EU Asks for Details on Anesthesia Risks for Weight-Loss Drugs
This article is for subscribers only.
European authorities have asked four companies, including Novo Nordisk A/S and Eli Lilly & Co., to provide more information about possible anesthesia complications from the use of weight-loss and diabetes drugs.
The European Medicines Agency’s safety committee, PRAC, made the request following a meeting in September where the popular weight-loss and diabetes drugs were discussed.